医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

A Technology Project of Beijing Handian Pharmaceutical: Honee Taishen Granule for COVID-19

2020年06月28日 PM12:18
このエントリーをはてなブックマークに追加


 

BEIJING

The research team of Handian Pharmaceutical Medical Center and Handian Traditional Chinese Medicine Hospital has devoted to develop a new formula against COVID-19, which in traditional Chinese medicine theory, is differentiated as cold-dampness viral disease with the symptoms of fever, aversion to cold, cough, fatigue, general aching pain, headache, diarrhea, etc. After several months of hardworking, they initially developed Honee Taishen Granule (also known as Handian HD1). Cooperating with Chinese Academy of Medical Sciences and Good Laboratory Practice (GLP) certification agencies, Handian Pharmaceutical Medical Center has completed pharmacy studies. Pharmacology and toxicology tests are still in progress to further evaluate its safety and efficacy.

This formula is derived from a famous traditional Chinese medicine prescription. Its components can eliminate dampness and turbidity, repel foulness and remove toxin, which give it cold-dampness eliminating and antiviral effects. According to traditional Chinese medicine theory, it rectifies taiyin cold damp constitution and restores yin-yang balance of the body, which can help patients regain immunity and prevents the virus from affecting the spleen (pancreas) to damage the body.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200627005012/en/

CONTACT

For more information, please contact:

Xiaoteng Bai

Branding and strategy Manager

Beijing Handian Science & Technology (Group) Co., Ltd.

Email: Baixiaoteng@handian.com

Phone: +86 010 5690 3502

Website: http://www.hantien.com.cn/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists